KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Cash Flow (2019 - 2025)

Royalty Pharma's Net Cash Flow history spans 7 years, with the latest figure at -$320.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 1423.1% year-over-year to -$320.2 million; the TTM value through Dec 2025 reached -$55.0 million, down 112.17%, while the annual FY2025 figure was -$310.3 million, 168.65% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$320.2 million at Royalty Pharma, down from $702.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $921.6 million in Q2 2024 and bottomed at -$1.1 billion in Q3 2022.
  • The 5-year median for Net Cash Flow is -$21.0 million (2024), against an average of $45.8 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 376.84% in 2022 before it crashed 1423.1% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$259.8 million in 2021, then surged by 376.84% to $719.1 million in 2022, then rose by 7.44% to $772.6 million in 2023, then crashed by 102.72% to -$21.0 million in 2024, then plummeted by 1423.1% to -$320.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Net Cash Flow are -$320.2 million (Q4 2025), $702.6 million (Q3 2025), and -$437.4 million (Q1 2025).